We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
F star Therapeutics Inc | NASDAQ:FSTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.12 | 7.20 | 7.72 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
Under the Securities Exchange Act of 1934
|
(Amendment No. 1)*
|
F-star Therapeutics, Inc.
|
(Name of Issuer)
|
Common Stock, par value $0.0001 per share
|
(Title of Class of Securities)
|
30315R 107
|
(CUSIP Number)
|
December 31, 2021
|
(Date of Event Which Requires Filing of this Statement)
|
☐
|
Rule 13d-1(b)
|
☐
|
Rule 13d-1(c)
|
☒
|
Rule 13d-1(d)
|
1
|
NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). |
|
Merck Ventures B.V.
|
||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
|
(a)
|
||
(b) X
|
||
3
|
SEC USE ONLY
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
The Netherlands
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
|
5
|
SOLE VOTING POWER
|
75,140
|
||
6
|
SHARED VOTING POWER
|
|
0
|
||
7
|
SOLE DISPOSITIVE POWER
|
|
75,140
|
||
8
|
SHARED DISPOSITIVE POWER
|
|
0
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
75,140
|
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
0.1%
|
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
|
FI
|
1
|
NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). |
|
Merck B.V.
|
||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
|
(a)
|
||
(b) X
|
||
3
|
SEC USE ONLY
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
The Netherlands
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
|
5
|
SOLE VOTING POWER
|
75,140
|
||
6
|
SHARED VOTING POWER
|
|
0
|
||
7
|
SOLE DISPOSITIVE POWER
|
|
75,140
|
||
8
|
SHARED DISPOSITIVE POWER
|
|
0
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
75,140
|
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
0.1%
|
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
|
FI
|
1
|
NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). |
|
Merck KGaA
|
||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
|
(a)
|
||
(b) X
|
||
3
|
SEC USE ONLY
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
Germany
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
|
5
|
SOLE VOTING POWER
|
75,140
|
||
6
|
SHARED VOTING POWER
|
|
0
|
||
7
|
SOLE DISPOSITIVE POWER
|
|
75,140
|
||
8
|
SHARED DISPOSITIVE POWER
|
|
0
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
75,140
|
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
0.1%
|
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
|
FI
|
Item 1. | (a) | Name of Issuer |
|
(b) |
Address of Issuer’s Principal Executive Offices
|
Item 2. | (a) | Name of Person Filing |
|
• |
Merck Ventures B.V.
|
|
• |
Merck B.V.
|
|
• |
Merck KGaA
|
|
(b) |
Address of Principal Business Office or, if none, Residence
|
|
(c) |
Citizenship
|
|
(d) |
Title of Class of Securities
|
|
(e) |
CUSIP Number
|
Item 3. |
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
Item 4. |
Ownership.
|
Item 5. |
Ownership of Five Percent or Less of a Class.
|
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person.
|
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
|
Item 8. |
Identification and Classification of Members of the Group.
|
Item 9. |
Notice of Dissolution of Group.
|
Item 10. |
Certification.
|
1 Year F star Therapeutics Chart |
1 Month F star Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions